Kenvue to Identify New CEO as Part of Strategic Review
Kenvue, a consumer health company that manufactures brands such as Tylenol, Listerine and Band-Aid, has announced that Thibaut Mongon will no longer lead the company as CEO as it undergoes a strategic review to unlock growth and optimize the business.
Mongon has fully departed Kenvue, also stepping down from the board.
New Leadership
In the interim, Kirk Perry — a current director at Kenvue — moves into the CEO role, bringing 30 years of experience in consumer packaged goods, technology and business transformation working with companies such as Procter & Gamble, Google and Circana. In the meantime, the company has launched a search for a permanent replacement, being led by Heidrick & Struggles.
In his 23 years at P&G, Perry held several positions in general management and marketing, including president of global family care, VP of U.S. operations and North America marketing, and VP of North America baby care. He also serves as a board member of The J.M. Smucker Co.
Also: Kenvue hires chief data and analytics officer of Kenvue
Kenvue’s Overhaul
The move comes at a time when the company faces increased investor pressure to improve performance. Kenvue’s May forecast expects its annual profits to be flat year-over-year as it navigates a $150 million impact from tariffs.
As a result, Kenvue will be looking at various ways to simplify its portfolio and better align leadership to deliver near- and long-term value for shareholders. The strategic review is being led by a dedicated committee.
“The actions announced today are to ensure we have the right talent, brand portfolio and operational foundation to fully capitalize on those strengths, accelerate profitable growth and best position the company for future success,” said Larry Merlo, Kenvue’s chair of the board in a statement.
